Archive for October, 2008

Daily Record, The (Baltimore) - Md.-based Advancis Pharmaceutical Corp. freezes development, looks

Friday, October 31st, 2008

As Advancis Pharmaceutical Corp. faces growing losses and regulatory challenges, the Germantown-based drug firm is cutting costs by controlling staff size, freezing most of its development programs and actively seeking a partner for acquisition.
The company, which has only one commercialized product, the antibiotic Keflex, had a net loss of $41.99 million in 2006, compared with a $32.99 million loss for 2005.
Its revenue fo…

Malasseziasis in Dog: a Case Report in Nepal

Tuesday, October 28th, 2008

Case History:

Wesley, a 7-year-old maleGermon Shephord , was presented because of a nine-month history of hair loss and thickened, greasy skin. The dog was moderately pruritic, but the owner could not recall if pruritus had preceded or followed the appearance of the skin lesions. The dog seemed healthy otherwise. A vinegar and water solution had been used topically as well as selenium sulfide shampoo with minimal improvement. Prednisone was dispensed six months before pres…

Pediatrics for Parents - The new "Super Staph

Thursday, October 23rd, 2008

The superbugs are here, and your child may be at risk.
Widespread and inappropriate antibiotic use have encouraged the emergence of a “superbug” version of the familiar “Staph,” short for Staphylococcus aureus. Staph is a familiar source of infection, and many children carry the bacteria without symptoms, have mild skin infections such as impetigo, or infected hair follicles (folliculitis). It also causes wound in…

Pediatric Nursing - Pain in the neck

Friday, October 17th, 2008

This is a Pediatric Management Problem (PMP) designed to test your problem-solving and decision-making abilities.
Instructions: Read the PMP below. Then outline how you would assess and manage the problem. Finally, compare your rationale and decision to that listed in the shaded area,
Please submit material to: Jean Ivey, DSN, CRNP; Pediatric Nursing Journal; East Holly Avenue/Box 56; Pitman, NJ 08071-0056; (856) 256-2345 (fax)

Journal of Drugs in Dermatology - Furosemide-induced bullous pemphigoid: case report and review of literature

Wednesday, October 15th, 2008

Abstract
Bullous pemphigoid (BP) is an acquired autoimmune disease characterized by subepidermal vesicles and bullae. The etiology for BP is mostly idiopathic with the highest occurrence in elderly patients; however, it is now well-accepted that BP has been triggered by or associated with drug therapy. We present a case of furosemide-induced bullous pemphigoid and review the literature of drug-induced bullous pemphigoid (DIBP).
Introduction

Most Popular
10 Jo…

American Family Physician - Retapamulin 1% topical ointment for the treatment of impetigo

Saturday, October 11th, 2008

Retapamulin (Altabax) 1% ointment is a topical antibiotic labeled for use in adults and children older than nine months for the treatment of impetigo caused by methicillin-susceptible Staphylococcus aureus and Streptococcus pyogenes. It is in a new class of antibiotics called pleuromutilins. Retapamulin has a bacteriostatic mechanism of action similar to that of macrolides and clindamycin (Cleocin).
SAFETY
Four studies tha…

Journal of Drugs in Dermatology - FDA approval for new strengths of Keflex

Tuesday, October 7th, 2008

Advancis Pharmaceutical Corporation recently announced that the FDA approved its request for new strengths of Keflex (cephalexin capsules, USP). Keflex is a first-generation cephalosporin antibiotic that is indicated for the treatment of skin and skin structure infections. The current available strengths are 250 mg capsules, 500 mg capsules, and powder for oral suspension.

Related Results

Journal of Drugs in Dermatology - The impact of treating Staphylococcus Aureus infection and colonization on the clinical severity of atopic dermatitis

Thursday, October 2nd, 2008

Sponsors and Collaborators: Children’s Memorial Hospital, Society for Pediatric Dermatology, and Johnson & Johnson. We would like to perform a randomized investigator-blinded placebo-controlled study of children aged 6 months to 17 years with moderate to…